NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.46
-0.76 (-18.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.22
Open4.01
Bid3.18 x 1300
Ask4.75 x 1400
Day's Range3.22 - 4.01
52 Week Range3.12 - 8.61
Volume105,082
Avg. Volume123,553
Market Cap32.601M
Beta (3Y Monthly)-0.47
PE Ratio (TTM)N/A
EPS (TTM)-1.41
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.13
Trade prices are not sourced from all markets
  • Business Wire27 days ago

    Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that Gregory J. Flesher, Chief Executive Officer of Novus, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York City on Tuesday, October 2, 2018 at 9:30 AM Eastern Time.

  • Business Wire2 months ago

    Novus Therapeutics to Postpone Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has elected to postpone the previously announced public offering of its common stock due to market conditions, including valuation sensitivity at the current share price. As of June 30, 2018, the company had $19.2 million in cash and cash equivalents. Novus believes that its current cash will be sufficient to achieve several key milestones in 2019, including completion of its planned phase 1 clinical trials with OP-02 in healthy adults, children with otitis media with effusion (“OME”), and adults with acute otitis media (“AOM”).

  • Business Wire2 months ago

    Novus Therapeutics Announces Proposed Public Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. Novus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 900,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

  • Business Wire3 months ago

    Novus Therapeutics Reports Second Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended June 30, 2018.

  • Business Wire4 months ago

    Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), announced receipt of final meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held at the Company’s request to discuss its OP-02 development program in otitis media. “The FDA provided guidance on our planned 505(b)(2) development path for OP-02 and confirmed that no additional preclinical or clinical studies beyond our planned phase 1 safety study in healthy adults will be required before initiation of phase 2 studies in children 6-months of age or older with otitis media,” said Dr. Catherine C. Turkel, President of Novus Therapeutics, Inc.

  • Business Wire5 months ago

    Novus Therapeutics Reports First Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended March 31, 2018 and provided a corporate update.

  • Business Wire7 months ago

    Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter and year ended December 31, 2017 and provided a corporate update.

  • Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?
    Simply Wall St.10 months ago

    Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?

    Novus Therapeutics Inc (NASDAQ:NVUS), a USD$29.55M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...

  • PR Newswire11 months ago

    Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference

    IRVINE, Calif. , Nov. 21, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ...

  • Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?
    Simply Wall St.11 months ago

    Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?

    I am going to take a deep dive into Novus Therapeutics Inc’s (NASDAQ:NVUS) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • PR Newswire11 months ago

    Novus Therapeutics Reports Third Quarter 2017 Results

    IRVINE, Calif. , Nov. 8, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, ...

  • PR Newswirelast year

    Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President

    IRVINE, Calif., Nov. 6, 2017 /PRNewswire/ -- Novus Therapeutics, Inc. (NVUS), a development stage specialty pharmaceutical company focused on the development of products for disorders of the ear, nose, and throat (ENT), today announced that Catherine Turkel, Pharm.D., Ph.D. has been promoted to President.  Dr. Turkel joined the company in November 2015 as Senior Vice President of Clinical Research and Development and Chief Development Officer, with responsibility for U.S. research and development functions.  In this expanded role, Dr. Turkel will now be responsible global research and development as well as commercial strategy and development.